The Experts below are selected from a list of 29040 Experts worldwide ranked by ideXlab platform
Suzanne M Michalek - One of the best experts on this subject based on the ideXlab platform.
-
Synthesis and Evaluation of a QS-17/18-Based Vaccine Adjuvant
Journal of Medicinal Chemistry, 2019Co-Authors: Pengfei Wang, Đani Škalamera, Ping Zhang, Suzanne M MichalekAbstract:We have synthesized a QS-17/18 analogue (7) and evaluated its Adjuvant activity in the formulation with rHagB antigen. Compound 7 and QS-21 analogues 5 and 6 are presumably the major components of GPI-0100, a widely used complex mixture of semisynthetic derivatives of Quillaja saponaria (QS) Molina saponins. The QS-17/18 analogue 7 shows an Adjuvant activity profile similar to that of GPI-0100, potentiating mixed Th-1/Th-2 immune responses, which is different from those of QS-21 analogues 5 and 6 that probably only induce a Th2-like immunity. The combination of QS-17/18 and QS-21 analogues does not show a synergistic effect. These results suggest that QS-17/18 analogue 7 might be the active component of GPI-0100 responsible for its immunostimulant property. Therefore, compound 7 can not only be a structurally defined alternative to GPI-0100 but also provide a valuable clue for rational design of new QS-based Vaccine Adjuvants with better Adjuvant properties.
-
Synthesis and Evaluation of a QS-17/18-Based Vaccine Adjuvant
2019Co-Authors: Pengfei Wang, Ping Zhang, Đani Škalamera, Xianwei Sui, Suzanne M MichalekAbstract:We have synthesized a QS-17/18 analogue (7) and evaluated its Adjuvant activity in the formulation with rHagB antigen. Compound 7 and QS-21 analogues 5 and 6 are presumably the major components of GPI-0100, a widely used complex mixture of semisynthetic derivatives of Quillaja saponaria (QS) Molina saponins. The QS-17/18 analogue 7 shows an Adjuvant activity profile similar to that of GPI-0100, potentiating mixed Th-1/Th-2 immune responses, which is different from those of QS-21 analogues 5 and 6 that probably only induce a Th2-like immunity. The combination of QS-17/18 and QS-21 analogues does not show a synergistic effect. These results suggest that QS-17/18 analogue 7 might be the active component of GPI-0100 responsible for its immunostimulant property. Therefore, compound 7 can not only be a structurally defined alternative to GPI-0100 but also provide a valuable clue for rational design of new QS-based Vaccine Adjuvants with better Adjuvant properties
Yuliang Zhao - One of the best experts on this subject based on the ideXlab platform.
-
surface engineered gold nanorods promising dna Vaccine Adjuvant for hiv 1 treatment
Nano Letters, 2012Co-Authors: Ligeng Xu, Ye Liu, Zhiyun Chen, Wei Li, Ying Liu, Liming Wang, Yong Liu, Xiaochun Wu, Yinglu Ji, Yuliang ZhaoAbstract:With the intense international response to the AIDS pandemic, HIV Vaccines have been extensively investigated but have failed due to issues of safety or efficacy in humans. Adjuvants for HIV/AIDS Vaccines are under intense research but a rational design approach is still lacking. Nanomaterials represent an obvious opportunity in this field due to their unique physicochemical properties. Gold nanostructures are being actively studied as a promising and versatile platform for biomedical application. Herein, we report novel surface-engineered gold nanorods (NRs) used as promising DNA Vaccine Adjuvant for HIV treatment. We have exploited the effects of surface chemistry on the Adjuvant activity of the gold nanorod by placing three kinds of molecules, that is, cetyltrimethylammonium bromide (CTAB), poly(diallydimethylammonium chloride) (PDDAC), and polyethyleneimine (PEI) on the surface of the nanorod. These PDDAC- or PEI-modified Au NRs can significantly promote cellular and humoral immunity as well as T cell...
-
surface engineered gold nanorods promising dna Vaccine Adjuvant for hiv 1 treatment
Nano Letters, 2012Co-Authors: Ye Liu, Zhiyun Chen, Ying Liu, Liming Wang, Yong Liu, Yuliang Zhao, Yiming Shao, Chunying ChenAbstract:With the intense international response to the AIDS pandemic, HIV Vaccines have been extensively investigated but have failed due to issues of safety or efficacy in humans. Adjuvants for HIV/AIDS Vaccines are under intense research but a rational design approach is still lacking. Nanomaterials represent an obvious opportunity in this field due to their unique physicochemical properties. Gold nanostructures are being actively studied as a promising and versatile platform for biomedical application. Herein, we report novel surface-engineered gold nanorods (NRs) used as promising DNA Vaccine Adjuvant for HIV treatment. We have exploited the effects of surface chemistry on the Adjuvant activity of the gold nanorod by placing three kinds of molecules, that is, cetyltrimethylammonium bromide (CTAB), poly(diallydimethylammonium chloride) (PDDAC), and polyethyleneimine (PEI) on the surface of the nanorod. These PDDAC- or PEI-modified Au NRs can significantly promote cellular and humoral immunity as well as T cell proliferation through activating antigen-presenting cells if compared to naked HIV-1 Env plasmid DNA treatment in vivo. These findings have shed light on the rational design of low-toxic nanomaterials as a versatile platform for Vaccine nanoAdjuvants/delivery systems.
Ye Liu - One of the best experts on this subject based on the ideXlab platform.
-
surface engineered gold nanorods promising dna Vaccine Adjuvant for hiv 1 treatment
Nano Letters, 2012Co-Authors: Ligeng Xu, Ye Liu, Zhiyun Chen, Wei Li, Ying Liu, Liming Wang, Yong Liu, Xiaochun Wu, Yinglu Ji, Yuliang ZhaoAbstract:With the intense international response to the AIDS pandemic, HIV Vaccines have been extensively investigated but have failed due to issues of safety or efficacy in humans. Adjuvants for HIV/AIDS Vaccines are under intense research but a rational design approach is still lacking. Nanomaterials represent an obvious opportunity in this field due to their unique physicochemical properties. Gold nanostructures are being actively studied as a promising and versatile platform for biomedical application. Herein, we report novel surface-engineered gold nanorods (NRs) used as promising DNA Vaccine Adjuvant for HIV treatment. We have exploited the effects of surface chemistry on the Adjuvant activity of the gold nanorod by placing three kinds of molecules, that is, cetyltrimethylammonium bromide (CTAB), poly(diallydimethylammonium chloride) (PDDAC), and polyethyleneimine (PEI) on the surface of the nanorod. These PDDAC- or PEI-modified Au NRs can significantly promote cellular and humoral immunity as well as T cell...
-
surface engineered gold nanorods promising dna Vaccine Adjuvant for hiv 1 treatment
Nano Letters, 2012Co-Authors: Ye Liu, Zhiyun Chen, Ying Liu, Liming Wang, Yong Liu, Yuliang Zhao, Yiming Shao, Chunying ChenAbstract:With the intense international response to the AIDS pandemic, HIV Vaccines have been extensively investigated but have failed due to issues of safety or efficacy in humans. Adjuvants for HIV/AIDS Vaccines are under intense research but a rational design approach is still lacking. Nanomaterials represent an obvious opportunity in this field due to their unique physicochemical properties. Gold nanostructures are being actively studied as a promising and versatile platform for biomedical application. Herein, we report novel surface-engineered gold nanorods (NRs) used as promising DNA Vaccine Adjuvant for HIV treatment. We have exploited the effects of surface chemistry on the Adjuvant activity of the gold nanorod by placing three kinds of molecules, that is, cetyltrimethylammonium bromide (CTAB), poly(diallydimethylammonium chloride) (PDDAC), and polyethyleneimine (PEI) on the surface of the nanorod. These PDDAC- or PEI-modified Au NRs can significantly promote cellular and humoral immunity as well as T cell proliferation through activating antigen-presenting cells if compared to naked HIV-1 Env plasmid DNA treatment in vivo. These findings have shed light on the rational design of low-toxic nanomaterials as a versatile platform for Vaccine nanoAdjuvants/delivery systems.
Mary L. Disis - One of the best experts on this subject based on the ideXlab platform.
-
TLR7 agonist imiquimod is a potent Vaccine Adjuvant
Cancer Research, 2008Co-Authors: Yushe Dang, Wolfgang M. Wagner, Ekram Gad, Carmen M. Berger, Mary L. DisisAbstract:2844 Potent Adjuvants are key to successful vaccination against weakly immunogenic antigens such as those involved in cancer or chronic infection. In particular, agents that can recruit and activate dendritic cells (DC) in vivo may enhance immune responses generated during active immunization. We evaluated the Adjuvant effects of the TLR7 agonist imiquimod as compared with GM-CSF, which has been widely used as a Vaccine Adjuvant. Topical imiquimod elicited a profound inflammatory infiltrate at the application site. Although both topical imiquimod and intradermal GM-CSF as Adjuvant effectively induced the accumulation and activation of DC in draining lymph nodes (DLN), imiquimod preferentially stimulated the accumulation of skin Langerhans cells (CD11c+/CD86+/CD205+/CD8-) in DLN. The phenotypic difference in the DC mobilized by GM-CSF and imiquimod was accompanied by functional differences. Both GM-CSF and imiquimod augmented ova specific-CD4 T cell response in ova-tg mice when used in conjunction with CD4 peptide-based Vaccines, as demonstrated by in vivo proliferation of CFSE labeled DO11.10 cells. Although both GM-CSF and imiquimod stimulated OVA specific CD8 T cell responses in OVA-tg mice when immunized with a CD8 peptide, the response induced by imiquimod was of greater magnitude. Finally, imiquimod was markedly more effective in stimulating ova specific T cell immunity with a protein-based Vaccine as compared to GM-CSF. Thus, imiquimod is a potent Vaccine Adjuvant in promoting Th1 type of responses and has the potential for clinical use as a Vaccine Adjuvant.
Pengfei Wang - One of the best experts on this subject based on the ideXlab platform.
-
Synthesis and Evaluation of a QS-17/18-Based Vaccine Adjuvant
Journal of Medicinal Chemistry, 2019Co-Authors: Pengfei Wang, Đani Škalamera, Ping Zhang, Suzanne M MichalekAbstract:We have synthesized a QS-17/18 analogue (7) and evaluated its Adjuvant activity in the formulation with rHagB antigen. Compound 7 and QS-21 analogues 5 and 6 are presumably the major components of GPI-0100, a widely used complex mixture of semisynthetic derivatives of Quillaja saponaria (QS) Molina saponins. The QS-17/18 analogue 7 shows an Adjuvant activity profile similar to that of GPI-0100, potentiating mixed Th-1/Th-2 immune responses, which is different from those of QS-21 analogues 5 and 6 that probably only induce a Th2-like immunity. The combination of QS-17/18 and QS-21 analogues does not show a synergistic effect. These results suggest that QS-17/18 analogue 7 might be the active component of GPI-0100 responsible for its immunostimulant property. Therefore, compound 7 can not only be a structurally defined alternative to GPI-0100 but also provide a valuable clue for rational design of new QS-based Vaccine Adjuvants with better Adjuvant properties.
-
Synthesis and Evaluation of a QS-17/18-Based Vaccine Adjuvant
2019Co-Authors: Pengfei Wang, Ping Zhang, Đani Škalamera, Xianwei Sui, Suzanne M MichalekAbstract:We have synthesized a QS-17/18 analogue (7) and evaluated its Adjuvant activity in the formulation with rHagB antigen. Compound 7 and QS-21 analogues 5 and 6 are presumably the major components of GPI-0100, a widely used complex mixture of semisynthetic derivatives of Quillaja saponaria (QS) Molina saponins. The QS-17/18 analogue 7 shows an Adjuvant activity profile similar to that of GPI-0100, potentiating mixed Th-1/Th-2 immune responses, which is different from those of QS-21 analogues 5 and 6 that probably only induce a Th2-like immunity. The combination of QS-17/18 and QS-21 analogues does not show a synergistic effect. These results suggest that QS-17/18 analogue 7 might be the active component of GPI-0100 responsible for its immunostimulant property. Therefore, compound 7 can not only be a structurally defined alternative to GPI-0100 but also provide a valuable clue for rational design of new QS-based Vaccine Adjuvants with better Adjuvant properties
